




Nitrogen oxide levels in blood samples from controls and patients with RA

	Controls (n=53)	RA Patients (n=120)	P Value
Nitrogen oxide (μM)	8.34 ± 1.68	14.21 ± 0.87	<0.05




Migration levels of fibroblast-like synoviocytes isolated from patients with RA



Synoviocytes were exposed to a control treatment (IgG) or anti-citrullinated protein antibodies (ACPAs). Cells were obtained from 10 different RA patients, and the experiment was replicated 6 times for each patient and treatment.

Sun M et al. *Ann Rheum Dis.* 2019;78(12):1621-1631.

TNF- α response of macrophages exposed to IgG anti-citrullinated protein antibody (ACPA) in the absence or presence of IgM rheumatoid factor (RF)



Laurent L et al. *Ann Rheum Dis.* 2015;74(7):1425-1431.



Associations between major histocompatibility complex (MHC) class II gene variants and autoimmune diseases

Disease	Associated Genes and Alleles
Celiac disease	<i>HLA-DQA*0501-DQB1*0201</i>
Crohn's disease	<i>HLA-DRB1*0103, *04, *0701, and HLA-DRB3*0301</i>
Graves disease	<i>HLA-DRB1*03-DQB1*02-DQA1*0501</i>
Ulcerative colitis	<i>HLA-DRB1*0103 and *1502</i>

Handunnetthi L et al. *Genes Immun.* 2010;11(2):99-112.



Relationship between anti-citrullinated protein antibody (ACPA) status and percentage of patients with RA who progress radiologically at 10 years

	Progressors (n=74)	Non-Progressors (n=51)	P Value
ACPA-positive	74.7	35.3	<0.05
ACPA-negative	25.3	64.7	

Syversen SW et al. *Ann Rheum Dis.* 2008;67(2):212-217.




Association between PsA and select susceptibility loci in a case-control study

SNP	Gene/Region	Minor Allele	Frequency, Cases (n=576)	Frequency, Controls (n=480)	Odds Ratio
rs10484554	<i>HLA-C</i>	T	0.19	0.07	2.4
rs2395029	<i>HLA-B</i>	C	0.12	0.04	3.2
rs11209026	<i>IL23R</i>	T	0.04	0.08	0.52
rs6887695	<i>IL12B</i>	C	0.21	0.28	0.69

Liu Y et al. *PLoS Genet.* 2008;4(3):e1000041.

Percentage of patients with a clinical response, as assessed by Psoriatic Arthritis Response Criteria, among individuals with PsA treated with either a TNF- α inhibitor or placebo



Mease PJ. *Ann Rheum Dis.* 2002;61(4):298-304.



Risk of developing PsA associated with psoriasis features, compared to risk among patients without those features

Psoriasis Feature	Hazard Ratio
Scalp lesions	3.89
Nail dystrophy	2.93
Intergluteal/perianal lesions	2.35
≥3 affected sites	2.24

Wilson FC et al. *Arthritis Rheum.* 2009;61(2):233-239.



Number of patients with PsA who experienced a 20% improvement in American College of Rheumatology response criteria (ACR20) after being randomized to 24 weeks of treatment with an IL-12/23 inhibitor or placebo

	Placebo (%) n=206	IL-12/23 Inhibitor (%) n=409	P Value
ACR20 response	47 (22.8%)	188 (46.0%)	<0.0001

McInnes IB et al. *Lancet*. 2013;382(9894):780-789.



Number of patients with PsA who experienced a 20% improvement in American College of Rheumatology response criteria (ACR20) after being randomized to 3 months of treatment with a JAK inhibitor or placebo

	Placebo (%) n=131	JAK Inhibitor, 5 mg (%) n=131	JAK Inhibitor, 10 mg (%) n=132
ACR20 response	31 (24)	65 (50)*	62 (47)*

*P value vs placebo <0.001